Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 10/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459258 | 0.97 | IRAK4 (0.52) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10459245 | 0.82 | PIM1 (0.59) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10458794 | 0.82 | CHEK1 (0.41) | IRAK4CCNT1CDK4PRMT5 | |
| SCHEMBL10457566 | 0.82 | PIM1 (0.43) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10459431 | 0.81 | CCNT1 (0.50) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10459443 | 0.80 | PIM1 (0.53) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10324171 | 0.79 | PIM1 (0.47) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10459231 | 0.79 | PIM1 (0.47) | IRAK4CCNT1MAPK8MAPK9PIM1 | |
| SCHEMBL10457546 | 0.79 | CCNT1 (0.41) | IRAK4CCNT1CDK4PRMT5 | |
| SCHEMBL10458772 | 0.75 | IRAK4 (0.73) | IRAK4CCNT1MAPK8MAPK9PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029546-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148434-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | IRAK4 477/4885CCNT1 1647/4885MAPK8 242/4885 |
| US-20120184524-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | IRAK4 477/4885CCNT1 1647/4885MAPK8 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.